Genmab's Experimental Drug Shows Efficacy in Advanced Head and Neck Cancer Trial

Genmab's petosemtamab, combined with Keytruda, significantly reduced the risk of death by half in a late-stage trial for PD-L1 positive head and neck squamous cell carcinoma. The experimental drug met its primary objectives for response rates and survival, indicating a potential new treatment option for this aggressive cancer. This positive outcome led to a surge in Genmab's shares.